$13.7 billion urgently needed to fight covid, says World Health Organization led coalition

Germany France Italy and the Netherlands have signed a deal to access 400 million doses of an experimental coronavirus vaccine

Adhanom Ghebreyesus said the pandemic has highlighted the importance of global solidarity and that health should not be seen as a cost but an investment.

While the Director-General said the situation in the European Union has improved significantly, he underlined that COVID -19 is very much still circulating globally, with more than four million new cases in the last month.

By the end of 2021, the World Health Organization plans to deliver about 2 billion doses of a coronavirus vaccine to people across the globe, WHO officials announced during a virtual media briefing on Friday.

The Access to covid-19 Tools ACT-Accelerator, is a new, groundbreaking global collaboration to accelerate the development, production, and equitable access to covid-19 diagnostics, therapeutics, and vaccines. Several Members of European Parliament underlined the importance of the World Health Organization but also said it has made mistakes in its response to the pandemic.

As coronavirus cases continue to decline in the UK, Oxford scientists are doing human trials for a possible coronavirus vaccine in Africa and Brazil, where more people are being exposed to the virus. It will start its work soon, he said.

Answering a question, Dr. Soumya Swaminathan, WHO'S chief scientist, said that the British-Swedish pharma company AstraZeneca's COVID-19 vaccine candidate is probably "the world's leading candidate and most advanced in terms of development". There is a hope that vaccines will be ready in 12 -18 months. The report said that this vaccine candidate mRNA-1273 after the initiation of the second phase of clinical trials has signed a deal with Catalent Inc. Between these, the World Health Organisation (WHO) has identified Oxford's COVID-19 vaccine- AstraZeneca as the front-runner.

The problem is that investing in vaccine development can be risky, since 80 percent of vaccines in early stage development fail before reaching clinical trials.

Brazil has so far reported over 55,000 deaths from the novel coronavirus and more than 1.2 million cases.